Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Operations: 2020-2025

Historic Cash from Operations for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -$10.9 million.

  • Silence Therapeutics' Cash from Operations rose 57.43% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.5 million, marking a year-over-year decrease of 15.79%. This contributed to the annual value of -$67.6 million for FY2024, which is 36.75% down from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Cash from Operations is -$10.9 million, which was up 49.98% from -$21.8 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Cash from Operations registered a high of $36.4 million during Q2 2021, and its lowest value of -$27.5 million during Q4 2024.
  • Its 3-year average for Cash from Operations is -$15.4 million, with a median of -$12.3 million in 2025.
  • Its Cash from Operations has fluctuated over the past 5 years, first spiked by 73.28% in 2021, then plummeted by 429.09% in 2022.
  • Quarterly analysis of 5 years shows Silence Therapeutics' Cash from Operations stood at -$3.0 million in 2021, then crashed by 429.09% to -$15.7 million in 2022, then plummeted by 42.66% to -$22.4 million in 2023, then decreased by 22.48% to -$27.5 million in 2024, then soared by 57.43% to -$10.9 million in 2025.
  • Its Cash from Operations was -$10.9 million in Q3 2025, compared to -$21.8 million in Q2 2025 and -$12.3 million in Q1 2025.